The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
37972429
DOI
10.1016/j.vhri.2023.10.001
PII: S2212-1099(23)00109-7
Knihovny.cz E-zdroje
- Klíčová slova
- direct costs, elasticity factor, friction period, indirect costs, loss of productivity,
- MeSH
- biologické přípravky * terapeutické užití MeSH
- finanční stres MeSH
- lidé MeSH
- náklady na zdravotní péči MeSH
- osobní újma zaviněná nemocí MeSH
- revmatoidní artritida * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biologické přípravky * MeSH
OBJECTIVES: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021. METHODS: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages. RESULTS: The average productivity loss reached €2984.54 in 2019, €3338.46 in 2020, and €3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of €8.4 million, €10.1 million, and €8.1 million, respectively. CONCLUSIONS: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
Citace poskytuje Crossref.org
